Pharsight

1. Namenda patent expiration

Treatment: Treatment of moderate to severe dementia of the alzheimer's type

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5061703 (Pediatric)	ALLERGAN	Adamantane derivatives in the prevention and treatment of cerebral ischemia	Oct, 2015 (10 years ago)
US5061703	ALLERGAN	Adamantane derivatives in the prevention and treatment of cerebral ischemia	Apr, 2015 (10 years ago)

Market Authorisation Date: 18 April, 2005

Dosage: SOLUTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
5 mg and 10 mg	16 Oct, 2007	14	30 Jan, 2015	11 Apr, 2015	Eligible

Strength	Dosage	Availability
2MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION	Discontinued

Treatment: Treatment of moderate to severe dementia of the alzheimer's type

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5061703 (Pediatric)	ABBVIE	Adamantane derivatives in the prevention and treatment of cerebral ischemia	Oct, 2015 (10 years ago)
US5061703	ABBVIE	Adamantane derivatives in the prevention and treatment of cerebral ischemia	Apr, 2015 (10 years ago)

Market Authorisation Date: 16 October, 2003

Dosage: TABLET